FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158312983> ?p ?o ?g. }

• W2158312983 endingPage "210" @default.
• W2158312983 startingPage "200" @default.
• W2158312983 abstract "Nuclear factor-kappaB (NF-κB) is constitutively activated in a variety of human cancers including prostate cancer and involved in tumorigenesis, tumor progression and chemo-resistance. Insulin-like growth factor-binding protein-3 (IGFBP-3) is a potent tumor suppressor and is significantly suppressed in a variety of cancers. Diverse biological effects of IGFBP-3 have been reported to be both dependent and independent of the IGF/IGF-I receptor (IGF-IR) axis. The precise underlying mechanisms of IGF/IGF-IR-independent, antiproliferative actions of IGFBP-3 are yet to be elucidated. We found an inverse correlation between NF-κB activity and IGFBP-3 expression during prostate cancer progression using an in vitro prostate cancer progression model. Restoration of IGFBP-3 resulted in significant inhibition of constitutively elevated NF-κB activity in prostate cancer cells. IGFBP-3 further inhibited the expression of NF-κB-regulated angiogenic factors such as VEGF and IL-8, and cell adhesion molecules, ICAM-1 and VCAM-1. This inhibitory action of IGFBP-3 was IGF/IGF-IR-independent since IGFBP-3 mutant devoid of IGF binding affinity had a similar inhibitory effect. We identified that IGFBP-3 degrades the key NF-κB regulatory molecules-IκBα and p65-NF-κB proteins through activation of caspase-8 and -3/-7, thereby inhibiting elevated NF-κB activity in prostate cancer. Finally intratumoral administration of IGFBP-3 resulted in significant tumor suppression as well as sensitization of antitumor effect of doxorubicin. Our findings indicate that IGFBP-3 exerts antitumor effects via IGF-independent mechanisms which involve activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. The use of IGFBP-3 as a cancer therapeutic with this distinctive suppression mechanism may offer alternate means to treat chemotherapy resistant tumors." @default.
• W2158312983 created "2016-06-24" @default.
• W2158312983 creator A5010399783 @default.
• W2158312983 creator A5014349504 @default.
• W2158312983 creator A5056791334 @default.
• W2158312983 creator A5083615070 @default.
• W2158312983 date "2011-08-01" @default.
• W2158312983 modified "2023-10-18" @default.
• W2158312983 title "Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling" @default.
• W2158312983 cites W1807380980 @default.
• W2158312983 cites W1911366696 @default.
• W2158312983 cites W1964176624 @default.
• W2158312983 cites W1966458578 @default.
• W2158312983 cites W1978008638 @default.
• W2158312983 cites W1980256068 @default.
• W2158312983 cites W1983097445 @default.
• W2158312983 cites W1983987321 @default.
• W2158312983 cites W1997806989 @default.
• W2158312983 cites W2011369409 @default.
• W2158312983 cites W2020636054 @default.
• W2158312983 cites W2030982520 @default.
• W2158312983 cites W2031014556 @default.
• W2158312983 cites W2038259382 @default.
• W2158312983 cites W2044826176 @default.
• W2158312983 cites W2054804338 @default.
• W2158312983 cites W2061369977 @default.
• W2158312983 cites W2062943475 @default.
• W2158312983 cites W2070885297 @default.
• W2158312983 cites W2071085645 @default.
• W2158312983 cites W2075172606 @default.
• W2158312983 cites W2077956417 @default.
• W2158312983 cites W2096654508 @default.
• W2158312983 cites W2097693048 @default.
• W2158312983 cites W2098547168 @default.
• W2158312983 cites W2107417411 @default.
• W2158312983 cites W2122379933 @default.
• W2158312983 cites W2124579687 @default.
• W2158312983 cites W2131527529 @default.
• W2158312983 cites W2134060756 @default.
• W2158312983 cites W2135279270 @default.
• W2158312983 cites W2150081825 @default.
• W2158312983 cites W2156406678 @default.
• W2158312983 cites W2160943316 @default.
• W2158312983 cites W2165818500 @default.
• W2158312983 cites W2314325548 @default.
• W2158312983 cites W2999065750 @default.
• W2158312983 cites W4230424997 @default.
• W2158312983 cites W4238990420 @default.
• W2158312983 cites W4256099535 @default.
• W2158312983 cites W4379365691 @default.
• W2158312983 doi "https://doi.org/10.1016/j.canlet.2011.04.004" @default.
• W2158312983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21536375" @default.
• W2158312983 hasPublicationYear "2011" @default.
• W2158312983 type Work @default.
• W2158312983 sameAs 2158312983 @default.
• W2158312983 citedByCount "55" @default.
• W2158312983 countsByYear W21583129832012 @default.
• W2158312983 countsByYear W21583129832013 @default.
• W2158312983 countsByYear W21583129832014 @default.
• W2158312983 countsByYear W21583129832015 @default.
• W2158312983 countsByYear W21583129832016 @default.
• W2158312983 countsByYear W21583129832017 @default.
• W2158312983 countsByYear W21583129832018 @default.
• W2158312983 countsByYear W21583129832019 @default.
• W2158312983 countsByYear W21583129832020 @default.
• W2158312983 countsByYear W21583129832021 @default.
• W2158312983 countsByYear W21583129832022 @default.
• W2158312983 countsByYear W21583129832023 @default.
• W2158312983 crossrefType "journal-article" @default.
• W2158312983 hasAuthorship W2158312983A5010399783 @default.
• W2158312983 hasAuthorship W2158312983A5014349504 @default.
• W2158312983 hasAuthorship W2158312983A5056791334 @default.
• W2158312983 hasAuthorship W2158312983A5083615070 @default.
• W2158312983 hasConcept C121608353 @default.
• W2158312983 hasConcept C170493617 @default.
• W2158312983 hasConcept C185592680 @default.
• W2158312983 hasConcept C190283241 @default.
• W2158312983 hasConcept C2775960820 @default.
• W2158312983 hasConcept C2777730290 @default.
• W2158312983 hasConcept C2780192828 @default.
• W2158312983 hasConcept C2780378035 @default.
• W2158312983 hasConcept C2780689927 @default.
• W2158312983 hasConcept C502942594 @default.
• W2158312983 hasConcept C54355233 @default.
• W2158312983 hasConcept C55493867 @default.
• W2158312983 hasConcept C555283112 @default.
• W2158312983 hasConcept C62478195 @default.
• W2158312983 hasConcept C86803240 @default.
• W2158312983 hasConcept C95444343 @default.
• W2158312983 hasConcept C96232424 @default.
• W2158312983 hasConceptScore W2158312983C121608353 @default.
• W2158312983 hasConceptScore W2158312983C170493617 @default.
• W2158312983 hasConceptScore W2158312983C185592680 @default.
• W2158312983 hasConceptScore W2158312983C190283241 @default.
• W2158312983 hasConceptScore W2158312983C2775960820 @default.
• W2158312983 hasConceptScore W2158312983C2777730290 @default.
• W2158312983 hasConceptScore W2158312983C2780192828 @default.
• W2158312983 hasConceptScore W2158312983C2780378035 @default.

• next